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Abstract
Introduction
Animal studies have shown Zoledronic Acid (ZA) may diminish pleural fluid accumulation
and tumour bulk in malignant pleural disease (MPD). We performed a pilot study to evaluate
its effects in humans.
Methods
We undertook a single centre, double-blind, placebo-controlled trial in adults with MPD. Pa-
tients were randomised (1:1) to receive 2 doses of intravenous ZA or placebo, 3 weeks
apart and were followed-up for 6 weeks. The co-primary outcomes were change in Visual
Analogue Scale (VAS) score measured breathlessness during trial follow-up and change in
the initial area under the curve (iAUC) on thoracic Dynamic Contrast Enhanced Magnetic
Resonance Imaging (DCE-MRI) from randomisation to week 5. Multiple secondary end-
points were also evaluated.
Results
Between January 2010 and May 2013, 30 patients were enrolled, 24 randomised and 4
withdrew after randomisation (1 withdrew consent; 3 had a clinical decline). At baseline, the
ZA group were more breathless, had more advanced disease on radiology and worse quali-
ty of life than the placebo group. There was no significant difference between the groups
with regards change in breathlessness (Adjusted mean difference (AMD) 4.16 (95%CI −4.7
to 13.0)) or change in DCE-MRI iAUC (AMD −15.4 (95%CI −58.1 to 27.3). Two of nine
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(22%) in the ZA arm had a>10% improvement by modified RECIST (vs 0/11 who received
placebo). There was no significant difference in quality of life measured by the QLQ-C30
score (global QOL: AMD -4.1 (-13.0 to 4.9)), side effects or serious adverse event rates.
Conclusions
This is the first human study to evaluate ZA in MPD. The study is limited by small numbers
and imbalanced baseline characteristics. Although no convincing treatment effect was iden-
tified, potential benefits for specific subgroups of patients cannot be excluded. This study
provides important information regarding the feasibility of future trials to evaluate the effects
of ZA further.
Trial Registration
UK Clinical Research Network ID 8877 ISRCTN17030426 www.isrctn.com
Introduction
Malignant pleural disease signifies incurable malignancy and management options are limited.
Symptomatic malignant pleural effusion (MPE) may be managed with drainage procedures
and/or pleurodesis, but currently available treatment strategies do not target the underlying
problem of excessive pleural fluid production. Additionally, patients may be too frail to under-
go tumour specific chemotherapy and hence treatment is often supportive.
Zoledronic Acid (ZA) is an intravenous aminobisphosphonate, which is currently licensed
for prevention of skeletal related events in adults with advanced cancer involving bone and
treatment of tumour-induced hypercalcaemia. It has well documented anti-tumour, anti-in-
flammatory and anti-angiogenic effects [1, 2]. These properties are appealing in malignant
pleural disease as they would target both the underlying tumour and the uncontrolled produc-
tion of pleural fluid. Exploratory in vivo and in vitro animal studies evaluating ZA in malignant
pleural disease have also shown encouraging results [3–7].
Along with its favourable safety profile, allowing ZA to be used in patients otherwise unfit
for chemotherapy, this makes it an attractive potential treatment for patients with malignant
pleural disease.
The aim of this study was to generate pilot clinical data regarding the efficacy of ZA in ma-
lignant pleural disease in order to inform a future, suitably powered randomised controlled
trial should the results show promise.
Materials and Methods
The protocol for this trial and supporting CONSORT checklist are available as supporting in-
formation; see S1 CONSORT Checklist and S1 Protocol.
Trial Design
The Bristol Randomised Trial of Zoledronic Acid in Malignant Pleural Disease (Pilot Study) was
a double-blind, placebo controlled, randomised trial. Ethical and regulatory approval for the
study was obtained from the SouthWest Research Ethics Committee (REC 09/H0206/12) and
the Medicines and Healthcare products Regulatory Agency (MHRA EudraCT 2009-009134-32)
Zoledronic Acid in Malignant Pleural Disease
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before recruitment commenced. After written informed consent, patients were randomised to re-
ceive 2 doses of intravenous ZA or placebo 3 weeks apart.
Participants Enrolled
Adults with malignant pleural thickening (with or without pleural effusion) were enrolled into
the study. The diagnosis of malignant pleural disease required positive pleural fluid cytology
and/or pleural biopsy, or a clinically confident diagnosis of MPE in the context of proven
cancer elsewhere.
The exclusion criteria were: Pleurodesis in the preceding 30 days; iv bisphosphonates ad-
ministered within the past 3 months; ongoing dental disease; significant renal impairment (cal-
culated creatinine clearance (CrCl)<40ml/min); hypocalcaemia; inability to give informed
consent; pregnancy or lactation; known allergy to bisphosphonates or its excipients; life expec-
tancy<4 months; current or planned chemotherapy; hormone manipulation therapy initiated
in the month prior to trial entry; age<18 years; haematological malignancy; severe
visual impairment.
Minor alterations made to the eligibility criteria during the recruitment period are detailed
in the online S1 Protocol.
Patients were identified from the pleural and oncology clinics and the lung cancer multi-dis-
ciplinary team (MDT) meeting at North Bristol NHS Trust. Eligible patients were provided
with a patient information sheet (see online S1 File: Patient information sheet) and written
consent was obtained.
Randomisation
Patients were randomised 1:1 to either ZA or placebo using minimisation. A random element
was used, so that patients were assigned to the treatment arm which minimised the imbalance
with a 95% probability. The minimisation factors were: the presence or absence of trapped
lung; tumour type (mesothelioma/ other); and the presence or absence of an indwelling pleural
catheter (IPC). Randomisation was performed using a centralised online randomisation service
(Sealed Envelope, London, UK).
Blinding
Patients, clinicians and trial investigators were blind to treatment allocation. The ZA and place-
bo preparations were indistinguishable. The radiology and biological samples were analysed
and the statistical analysis plan finalised prior to un-blinding.
Trial Interventions
The full details of the study protocol are available in the online S1 Protocol. After written con-
sent (see S2 File: Consent form), patients had a 2 week run-in period to confirm study eligibility
and undergo baseline assessments. All patients underwent a dental check and any necessary
dental treatment during the run-in period to minimise the risk of osteonecrosis of the jaw (as
per the guidance in the summary of product characteristics for Zoledronic Acid).
The dose of ZA was calculated according to their estimated CrCl (CrCl60ml/min: 4mg
ZA; CrCl50-<60ml/min: 3.5mg ZA; CrCl40-<50ml/min: 3.3mg ZA) and provided by the
pharmacy in 100ml 0.9% sodium chloride. The placebo was 100ml 0.9% sodium chloride. A
second dose of Investigational Medicinal Product (IMP) was administered 3 weeks later.
All participants received other treatments during trial follow up in accordance with stan-
dard care guidelines.
Zoledronic Acid in Malignant Pleural Disease
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Trial Assessments
Patients were followed for 6 weeks after randomisation. Patients completed a daily Visual Ana-
logue Scale (VAS) score assessing breathlessness for a week prior to randomisation until the
end of trial follow-up. The European Organisation for Research and Treatment of Cancer
Quality of Life Questionnaire (EORTC-QLQ-C30) [8], the Edmonton Symptom Assessment
System (ESAS) QOL questionnaire, Medical Research Council (MRC) dyspnoea score and tho-
racic ultrasound (USS) were completed at randomisation, week 3 and week 6. A CT and MRI
thorax were performed in the week prior to randomisation and during week 5 (see S1 Protocol,
S3 File and S4 File: SOP for DCEMRI analysis for scan protocols). Patients with an indwelling
pleural catheter (IPC) underwent twice weekly drainages and fluid was stored at −80°C for fu-
ture analysis (see S3 File). Blood tests were performed on a weekly basis for monitoring pur-
poses and samples were stored at −80°C for future analysis (see S3 File).
Trial Outcomes
The primary endpoints were: (1) Change from baseline to week 5 in the ‘initial area under the
curve measurement for the first 90 seconds’ (iAUC) of the DCE-MRI scan and (2) The summa-
ry score for the dyspnoea VAS score from randomisation to week 6 post-randomisation.
The main objective of this pilot trial was to assess potential efficacy of ZA in this patient
group to inform a future, suitably powered RCT. Therefore numerous secondary clinical and
feasibility outcomes were evaluated over the 6 week trial follow up (see S5 file: Statistical analy-
sis plan for full details). This included changes from baseline to week 5 in Dynamic Contrast
Enhanced MRI (DCE-MRI) and Diffusion weighted MRI (DWI-MRI) parameters; modified
response evaluation in solid tumours (RECIST) scores; CT measured pleural thickening and ef-
fusion volumes. Also, changes in USS effusion depths; quality of life and symptom control
(using the EORTC QLQ-C30, ESAS score and Medical Research Council (MRC) dyspnoea
scale) and blood parameters (serum mesothelin, plasma VEGF-A, plasma IL-6, MCP-1, serum
neutrophil to lymphocyte ratio (NLR)) recorded at baseline, week 3 and week 6 were assessed.
For patients with an IPC, weekly pleural fluid VEGF-A and MCP-1 levels and pleural fluid pro-
duction were also evaluated. Pharmacokinetic analysis of ZA levels in the pleural fluid and
pharmacokinetic analysis of the DCE-MRI scans was planned but was unable to be performed
due to resource issues.
The CT and MRI scans were reported independently by 2 respiratory radiologists and dis-
crepancies resolved by consensus. Further details on the reporting methods can be found in S1
Protocol, S3 File and S4 File: SOP for DCEMRI analysis.
Safety outcomes were also evaluated up to 6 weeks post-randomisation. This included the
number of patients: (1) experiencing at least one known side effect of Zoledronic Acid; (2)
experiencing at least one serious adverse event; and (3) requiring an increase in calcium, mag-
nesium or phosphate replacement [9]. The side effects were categorized based on the partici-
pants’ case report forms and blood results prior to un-blinding of the patients’ treatment
allocations.
Statistical Methods
Data was analysed on intention-to-treat principles. All randomised patients in whom an out-
come was available were included in the analysis. Data collected up to the point of patient with-
drawal were included. All analyses were pre-determined prior to data analysis and un-blinding.
All analyses adjusted for outcome value measured at baseline (if recorded) and the minimisa-
tion factors (the presence or absence of trapped lung; tumour type (mesothelioma/ other); the
presence or absence of an IPC) [10–12]. Mean imputation was used to account for baseline
Zoledronic Acid in Malignant Pleural Disease
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variables with missing data [13]. All outcomes were analysed using a linear regression model
except for the main adverse event outcomes, which were analysed using logistic regression. The
linear regression models provided an adjusted mean difference (AMD) to quantify the treat-
ment effect. The linear regression models reported treatment effect as Odds Ratios.
Outcomes which were collected at multiple time points during trial follow up (VAS scores,
QOL measures, blood and pleural fluid biomarkers, pleural fluid production and USS depths)
were analysed using a ‘summary score’, which was calculated by dividing the area under the
curve (AUC) by the number of days that the patient remained in the study (to account for dif-
ferent durations of follow-up). The AUC was calculated using the trapezium rule [14].
Stata software version 13 (Texas, USA) was used for analyses. Full details of the statistical
analysis plan are in the online S5 File: Statistical analysis plan.
The trial was registered with the MHRA (EudraCT 2009-009134-32) and the UK Clinical
Research Network (UKCRN ID 8877) prior to recruitment commencing. It was subsequently
also registered with an International Standard Randomised Controlled Trial Number
ISRCTN17030426.
Sample Size Calculation
The study was designed as a proof of principle, pilot study and was the first time ZA had been
used in humans for this indication. Therefore, a power calculation was not feasible. However, a
target recruitment of 40 patients was chosen and subsequently reduced to 30 due to difficulties
with recruitment.
Trial Funding
This trial was supported by unrestricted research grants from North Bristol NHS Trust (small
grants scheme), Novartis and UKMedical. The study was sponsored by North Bristol NHS
Trust. The IPCs and drainage bottles were provided by UKMedical. The funders had no
role in study design, data collection and analysis, decision to publish or preparation of the
manuscript.
Results
Feasibility Outcomes
The patient flow diagram is shown in Fig. 1. The trial was granted ethics approval on 18/05/
2009. 30/61 screened patients (49%) were recruited from North Bristol NHS Trust between 5th
January 2010 and 8th May 2013. The final patient completed trial follow up on 2nd July 2013.
24/30 consented patients (80%) were subsequently randomised and 20 patients completed the
trial follow up. 11/30 consented patients were found to have poor dentition at their baseline
dental assessment, 2 of whom were withdrawn from the study and 9 required dental interven-
tion prior to ongoing trial involvement. Reasons for the exclusions and withdrawals are given
in Fig. 1.
Two of the 24 randomised patients did not receive any doses of study treatment (1 patient
withdrew consent, 1 patient withdrawn due to clinical decline) and 2 patients received only
one dose (1 patient declined second dose; 1 patient withdrawn prior to 2nd dose due to clinical
decline). The remaining 20 patients (83%) received both doses (see online S3 File).
2/11 patients who received ZA required a dose reduction (1 due to low CrCl and 1 due to
‘flu-like symptoms after the first dose).
Zoledronic Acid in Malignant Pleural Disease
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Patients
Baseline characteristics are presented in Table 1. There were a number of imbalances between
the study arms. There were more males in the placebo group compared to the ZA group (85%
vs 45%). The placebo group were less breathless than the ZA group at randomisation, as mea-
sured by the MRC dyspnoea score (2.3 (SD 1.1) vs 3.1 (SD 1.1)), dyspnoea VAS score (22.9mm
(SD 12.3) vs 33.5mm (SD 15.2)) and QLQ-C30 dyspnoea score (27.8 (SD 13.0) vs 56.7 (SD
22.5)).
The placebo group also had a better baseline QOL compared to the ZA group, with a mean
QLQ-C30 overall QOL score of 67.4 (SD 20.6) and 55.8 (SD 11.8), a mean QLQ-C30 physical
functioning score of 72.8 (SD 16.4) and 62.7 (SD 19.7) respectively and a mean ESAS score of
15.9 (SD 7.7) and 24.1 (SD 9.9) respectively.
Additionally, at randomisation the placebo group had less advanced disease on radiology
than the ZA group, with a mean baseline modified RECIST score of 55.6 (SD 30.3) and 63.9
(SD 34.2) respectively. The placebo group also had a lower baseline DCE-MRI iAUC at base-
line than the ZA group (113.9 (SD 49.9) vs 128.1 (57.6) respectively).
There were a number of other small differences between the treatment groups at baseline,
although the relevance of these in terms of any potential treatment effect is not clear. A smaller
proportion of patients in the placebo group had received previous chemotherapy (6/13 vs 7/11
Fig 1. Patient flow diagram.
doi:10.1371/journal.pone.0118569.g001
Zoledronic Acid in Malignant Pleural Disease
PLOS ONE | DOI:10.1371/journal.pone.0118569 March 17, 2015 6 / 16
Table 1. Baseline characteristics of the randomised patients.
Placebo (n =
13)
Zoledronic Acid (n =
11)
Male, n (%) 11 (85) 5 (45)
Age, mean (SD) 72.6 (9.9) 71.2 (8.3)
Side
Left, n (%) 4 (31) 4 (36)
Right, n (%) 9 (69) 6 (55)
Bilateral, n (%) 0 1 (9)
Cell type
Mesothelioma, n (%) 7 (54) 7 (64)
Lung Cancer, n (%) 3 (23) 3 (27)
Other, n (%) 3 (23) 1 (9)
Presence of malignant pleural effusion, n (%) 11 (85) 8 (73)
Mode of diagnosis
Pleural biopsy, n (%) 8 (62) 7 (64)
Pleural fluid cytology, n (%) 4 (31) 3 (27)
Other, n (%) 1 (8) 1 (9)
Time from diagnosis to trial entry, days, median (IQR) 180 (105–293) 205 (48–241)
Previous chemotherapy 6 (46) 7 (64)
On steroids at trial entry, n (%) 2 (15) 1 (9)
Previous talc pleurodesis, n (%) 4 (31) 2 (18)
Previous thoracic surgery, n (%) 1 (8) 2 (18)
IPC in situ at trial entry, n (%) 4 (31) 2 (18)
Trapped lung, n (%) 3 (23) 2 (18)
Dental treatment required in study run-in period, n (%) 3 (25) 6 (55)
Imaging
DCE-MRI ‘area under the curve in the first 90s’ (iAUC),
mean (SD)
113.9 (49.9) 128.1 (57.6)
Modified RECIST score, mean (SD) 55.6 (30.3) 63.9 (34.2)
Summed ultrasound effusion depth, mean (SD) 8.6 (11.5) 5.0 (5.8)
Blood tests
Serum WCC, mean (SD) 11.3 (10.4) 8.3 (3.2)
Haemoglobin, mean (SD) 12.7 (1.7) 12.7 (2.1)
Platelets, mean (SD) 280 (102) 345 (126)
Creatinine clearance, mean (SD) 72.6 (17.1) 81.6 (19.4)
Corrected calcium, mean (SD) 2.4 (0.2) 2.4 (0.1)
Phosphate, mean (SD) 1.2 (0.2) 1.1 (0.2)
Magnesium, mean (SD) 0.79 (0.08) 0.80 (0.06)
NLR, mean (SD) 6.0 (6.6) 4.0 (3.6)
Quality of life
EORTC QLQC30- global quality of life, mean (SD) 67.4 (20.6) 55.8 (11.8)
EORTC QLQC30- physical functioning score, mean
(SD)
72.8 (16.4) 62.7 (19.7)
ESAS score, mean (SD) 15.9 (7.7) 24.1 (9.9)
Dyspnoea Scores
Dyspnoea VAS score (mm) 22.9 (12.3) 33.5 (15.2)
Bother about breathlessness VAS score 23.0 (13.1) 31.6 (14.6)
MRC dyspnoea score 2.3 (1.1) 3.1 (1.1)
(Continued)
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in the ZA group). More patients randomised to placebo had undergone a talc pleurodesis in
the past (4/13 vs 2/11 in the ZA group) and more were taking steroids at trial entry (2/13 vs 1/
11 in the ZA group).
No patients received any other systemic treatments for cancer during their trial
involvement.
Primary Outcomes
VAS Breathlessness Score. 22/24 randomised patients were included in the analysis of the
breathlessness VAS Score (1 withdrew consent; 1 provided no VAS score data post randomisa-
tion). As described above, patients in the ZA group had higher baseline VAS breathlessness
scores than those in the placebo arm.
There was no significant difference in the summary scores for the breathlessness VAS score
between treatment arms. The VAS summary score was 21.6 (SD 13.4; n = 12) in the placebo
arm compared with 34.0 (SD 15.0; n = 10) in the ZA group (adjusted mean difference (AMD)
4.2 (95%CI −4.7 to 13.0)). The change in mean VAS breathlessness score over time for the two
study arms is shown in Fig. 2.
There were insufficient patients with an IPC in-situ, trapped lung or who initiated chemo-
therapy or endocrine therapy during trial follow up to allow meaningful subgroup analyses.
Subgroup analysis of the mesothelioma patients did not show any important differences.
DCE-MRI. 16/24 randomised patients were included in the DCE-MRI analysis (4 patients
did not undergo either trial MRI scan; 3 had follow-up MRIs of insufficient quality due to
movement artefact; 1 had no second scan due to a clinical decline). There was no significant
difference in the change in the iAUC from baseline to week 5 in the placebo group vs the ZA
group (7.3 (SD 46.8; n = 9) and -20.9 (SD 20.4; n = 7) respectively; AMD -15.4 (95% CI −58.1
to 27.3)). This trend towards an improvement in perfusion in the ZA arm is likely to be due to
test-to-test variability rather than a true response, given the relative improvement in values for
some patients in both arms (see Fig. 3).
There were insufficient numbers to meaningfully perform the predefined
subgroup analyses.
Secondary Outcomes
Modified RECIST. 21 patients had a baseline modified RECIST score. 6/11 in the placebo
arm had measurable disease according to modified RECIST on their baseline scan, compared
to 7/10 in the ZA arm.
All 20 evaluable patients in the study had stable disease according to the modified RECIST
criteria. However, 2 patients in the ZA group had a>10% reduction in their modified RECIST
Table 1. (Continued)
Placebo (n =
13)
Zoledronic Acid (n =
11)
EORTC QLQC30- dyspnoea score, mean (SD) 27.8 (13.0) 56.7 (22.5)
SD = Standard Deviation; IPC = Indwelling pleural catheter; DCE-MRI = Dynamic Contrast Enhanced
Magnetic Resonance Imaging; RECIST = Response evaluation criteria in solid tumours; WCC = white cell
count; NLR = Neutrophil to Lymphocyte ratio; EORTC QLQ-C30 = European Organisation for Research
and Treatment of Cancer Quality of Life Questionnaire; ESAS = Edmonton Symptom Assessment Scale;
VAS = Visual Analogue Scale; MRC = Medical Research Council.
doi:10.1371/journal.pone.0118569.t001
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Fig 3. Change in DCE iAUC from baseline to week 5 (complete case data).
doi:10.1371/journal.pone.0118569.g003
Fig 2. Box and whisper plot evaluating the average weekly VAS breathlessness scores for the 2
treatment arms. The horizontal line with the box represents the median. The box edges represent the lower
(25th) and upper (75th) quartiles. The whiskers represent the lower and upper adjacent values. Outside values
are plotted separately.
doi:10.1371/journal.pone.0118569.g002
Zoledronic Acid in Malignant Pleural Disease
PLOS ONE | DOI:10.1371/journal.pone.0118569 March 17, 2015 9 / 16
score from baseline to week 5, compared with none in the placebo group (one patient with ade-
nocarcinoma of unknown primary had a 9mm (18%) improvement; one with mesothelioma
had an 8mm (11%) improvement) (see Fig. 4).
The mean change in the modified RECIST scores between the groups was not statistically
significant (3.3 (SD 6.1; n = 11) in placebo arm vs 1.7 (SD 7.4; n = 9) in the ZA arm; AMD -1.8
(95%CI −7.9 to 4.3)).
Breathlessness. All of the other tools used to evaluate patient dyspnoea (MRC dyspnoea
score, QLQ-C30 dyspnoea domain and ‘bother’ VAS score) showed similar trends in their re-
sults to the primary outcome VAS Score. The ZA group were consistently more breathlessness
at baseline and the treatment did not significantly alter breathlessness (see online S3 File: full
results).
Quality of life. All three of the quality of life tools evaluated (ESAS, QLQ-C30 global QOL
domain and QLQ-C30 physical functioning domain) showed consistent results. The ZA group
had worse QOL at baseline and there was no significant differences between the groups in
terms of the change in QOL during trial follow up (see online S3 File).
Dynamic Contrast Enhanced MRI. In addition to the primary endpoint, three other mea-
surements DCE-MRI parameters were evaluated (Change in the time-to-peak enhancement,
change in maximal percentage enhancement, change in the initial wash-in slope). None of the
DCE-MRI parameters revealed differences between the treatment arms (see online S3 File).
Neither patient who displayed an improvement in their modified RECIST scores had interpret-
able MRI data (MRI contraindicated in one and uninterpretable week 5 images for the other).
Diffusion weighted MRI. The numbers of patients with evaluable DWI-MRI imaging was
small (8/24). There was no significant difference between the 2 treatment groups (see online S3
File).
Fig 4. % Change in modified RECIST scores from baseline to week 5.
doi:10.1371/journal.pone.0118569.g004
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Biomarkers. Evaluating the changes in serum biomarkers over time (mesothelin, serum
VEGF, NLR, IL6 and MCP-1) there was no difference seen between the treatment arms (see
Fig. 5 and online S3 File).
Pleural fluid volumes. Only 6/24 randomised patients had IPCs in situ (4 in the placebo
arm and 2 in the ZA arm), therefore the numbers were too small for formal analysis. No differ-
ence was identified in IPC fluid output in these patients (see online S3 File).
Volumetric analysis of the effusion volume on CT (excluding patients with an IPC in situ or
those who had undergone a pleural aspiration during trial follow up), showed no significant
difference in the change in effusion volume from randomisation to week 5 between the 2 study
arms (AMD 10 (95%CI −14 to 34)).
Excluding those patients who underwent a pleural aspiration during trial follow up and
those with an IPC in situ, there was no difference between the treatment groups when evaluat-
ing the ultrasound summary scores for effusion volume (AMD 0.66 (95%CI −0.53 to 1.85)).
Safety. The frequency of adverse events are summarised in Table 2. 21/24 randomised pa-
tients experienced at least one side effect and the rate was comparable for the 2 treatment arms
(11/13 in placebo arm vs 10/11 in ZA arm; Odds Ratio (OR) 1.8 (95% CI 0.1–23.3)). Evaluating
the individual side effects separately, the rates were also comparable between the two arms of
the study, although slightly more patients experienced fever or ‘flu like syndrome in the ZA
group (4/11 vs 2/13 in the placebo group).
8/24 patients experienced a serious adverse event (5/13 in the placebo arm and 3/11 in the
ZA arm; OR 0.67 (95% CI 0.11 to 4.08)). Only one was potentially attributable to the study
drug (one patient in the ZA arm admitted with flu like symptoms and myalgia 2 days after the
first dose of IMP, which resulted in the patient declining the second dose). See online S3 File
for further details.
Fig 5. Box and whisper plot showing the change in blood biomarkers over time for the 2 treatment arms. The horizontal line with the box represents
the median. The box edges represent the lower (25th) and upper (75th) quartiles. The whiskers represent the lower and upper adjacent values. Outside values
are plotted separately.
doi:10.1371/journal.pone.0118569.g005
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Comparable numbers of patients required an increase in their calcium, magnesium or phos-
phate replacement during trial follow up (3/13 (23%) in placebo group vs 4/11 (36%) in the ZA
group; OR 2.5 (95%CI 0.3 to 19.3)).
Discussion
This is the first randomised controlled trial to evaluate the effects of Zoledronic Acid in pa-
tients with malignant pleural disease. We did not identify any differences in our primary out-
come measures, breathlessness and DCE-MRI. However, two patients who received ZA
demonstrated a>10% reduction in tumour bulk as assessed by modified RECIST compared to
none in the placebo arm. In addition the number and type of side effects were comparable be-
tween the two study arms.
There is a paucity of effective treatments for patients with malignant pleural disease. Effu-
sion management and chemotherapy may be the only options depending on the underlying
cell type [15, 16]. However, as a significant proportion of patients are unsuitable for chemo-
therapy due to poor baseline performance score or other comorbidities, there is a requirement
for less toxic treatments, which could be used in these frailer patient groups.
Aminobisophosphonates have anti-cancer activity in a number of tumour types through in-
hibition of farnesyl diphosphate (FPP) synthase (a key element of the mevalonate pathway), re-
sulting in impaired adhesion, migration and proliferation of cancer cells [1]. Additionally, they
have direct effects on immune cell activation and inhibit angiogenesis, both of which contrib-
ute to their anti-tumour effects. This has led to their widespread use in the treatment and pre-
vention of skeletal related events in cancer and increasing interest in their use as an adjuvant
treatment in other cancer types, particularly breast cancer [17].
There is compelling in-vivo and in-vitro evidence to suggest ZA may have beneficial effects
in malignant pleural disease. In a mouse model of lung adenocarcinoma affecting the pleural
cavity, ZA reduced pleural fluid accumulation and pleural tumour bulk, as well as prolonging
survival and limiting cachexia. These effects were associated with reduced new vessel formation
Table 2. Side effects and adverse events.
Side Effect Placebo, number affected
(%) (n = 13)
Zoledronic Acid, number
affected (%) (n = 11)
Any side effect 11 (85) 10 (91)
Haematological disorder 0 (0) 0 (0)
Rash 0 (0) 1 (9)
Headache 1 (8) 1 (9)
Fever or ‘Flu like syndrome 2 (15) 4 (36)
Myalgia/arthralgia 4 (31) 3 (27)
Renal disturbance 0 (0) 0 (0)
Eye disorder 0 (0) 1 (9)
Gastrointestinal symptoms 6 (46) 5 (45)
Dizziness 2 (15) 3 (27)
Lethargy 4 (31) 4 (36)
Electrolyte disturbance requiring
supplementation
3 (23) 4 (36)
Osteonecrosis of the jaw 0 (0) 0 (0)
Serious Adverse Event 5 (38) 3 (27)
doi:10.1371/journal.pone.0118569.t002
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and vascular permeability, a reduction in mononuclear cells in the pleural space and a reduc-
tion in pro-inflammatory and angiogenic mediators [7].
There is also in vitro evidence that ZA induces apoptosis in mesothelioma cells [4, 6, 18]
and favourably affects the host’s immune response to the tumour [5]. Mouse models of meso-
thelioma also suggest that ZA inhibits tumour growth and prolongs survival [3, 6]. This has led
to interest in using ZA in the treatment of malignant pleural disease. There are reports of it
being used off licence in mesothelioma [19], however a phase 2 study evaluating its use as an
adjuvant treatment for MPE due to non-small cell lung cancer closed prematurely after 3 pa-
tients were enrolled due to poor accrual [20].
CT is the current gold standard imaging modality for evaluation of the pleura and the modi-
fied RECIST criteria have been developed to stage and monitor treatment response in mesothe-
lioma [21, 22]. Unidimensional measurements from 6 areas of pleural thickening (2 sites at 3
levels) and any enlarged nodes are summed to give the modified RECIST score. The standard
definition of a partial response is at least a 30% reduction in this score on 2 occasions 4 weeks
apart, for all tumour types [23]. 2 patients in the ZA arm of this study showed a reduction in
tumour volume by modified RECIST of>10%, although this does not meet the above criteria
for a partial response.
However, these CT results should be interpreted carefully. A number of patients in the trial
had small volume disease which may make consistent measurement of pleural tumour thickness
more difficult [24]. Recently published data supports our decision to measure disease>5mm
and reporting by consensus in this trial aimed to standardise measurements and minimise bias
[24]. Additionally, the trial scans were performed only 5 weeks apart, which is a short time inter-
val to detect a treatment response.
DCE-MRI is a novel imaging method, which has recently shown some promise in the evalu-
ation of malignant pleural disease [25, 26]. It monitors the transit of contrast through the tis-
sues and hence characterises the tumour’s vascularity and vascular permeability. This makes it
an attractive imaging technique in pleural malignancy, where neovascularisation is felt to be
pathogenic and confers a worse prognosis [27]. However, the best technique for reporting
DCE-MRI is yet to be established and given the lack of robust, validated methodology, it does
not have an established role in routine clinical practice. We did not demonstrate a change in
DCE-MRI in response to treatment, which may reflect the analysis methods used and/or the
small number of patients with evaluable data.
In animal models, ZA reduces the expression of a number of pro-inflammatory and angio-
genic mediators, including VEGF, IL-6 and MCP-1 [7] and an observational study in mesothe-
lioma found falling levels of circulating VEGF to be a good prognostic factor after 8 weeks of
chemotherapy [28]. However, despite this and data from other cancer types also suggesting
Zoledronic Acid supresses circulating VEGF levels, we failed to show any treatment effect of
ZA on the blood biomarkers tested [29, 30]. We may have missed a local effect of the ZA on
these inflammatory mediators given the small numbers of patients with indwelling catheters in
the trial.
We did not demonstrate any benefit of ZA in terms of symptom control or quality of life
compared to placebo in this study. Given the advanced nature of the malignant disease in
many of the study patients and the resultant complex, multi-factorial nature of many of their
symptoms, this is not entirely surprising in this small cohort. The different tools used to evalu-
ate both overall quality of life and breathlessness all showed consistent results, suggesting that
measuring these symptoms with multiple different tools may not add value.
ZA did not appear to be associated with a marked increase in side effects compared to place-
bo. The side effect profile of ZA is well established due to its extensive use for other indications,
but it is reassuring that the treatment appeared to be well tolerated in this patient group [9].
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This study was designed as a proof-of-principle pilot study and hence has a number of limi-
tations. We excluded patients receiving other cancer treatments and given the frail nature of
this population, recruitment was challenging and the number of included patients is small. In
view of this, we were unable to recruit as many patients with indwelling pleural catheters as ini-
tially envisaged, limiting our ability to detect a potential signal regarding pleural fluid output
and pleural fluid biomarkers. The recruited patients were heterogeneous and the groups poorly
balanced for a number of variables at baseline, which may have contributed to the difficulties
in identifying a signal for a number of the outcome measures.
There is data from a number of cell types to suggest that the aminobisphosphonates may act
synergistically with chemotherapy. A recent study evaluating the potential synergistic effect of
intrapleural ZA with systemic Cisplatin chemotherapy in a mouse model of mesothelioma
showed combination therapy had greater anti-tumour effects than either agent used alone [18].
We did not evaluate this synergy in the current study, but may be interesting to explore in fu-
ture trials. We also await with interest the results of an open label trial of ZA in mesothelioma,
which is currently recruiting in Birmingham, Alabama [31].
In summary, the results of this small pilot study have not shown conclusive evidence of a
treatment effect of Zoledronic Acid in this population. However, given the small number of pa-
tients randomised and substantial baseline imbalances between the groups, we cannot exclude
a potential beneficial effect. We feel that a further pilot study in a more specific subgroup of pa-
tients is warranted to evaluate its effect further. We have learnt important lessons about the fea-
sibility of future studies and this data will help inform trial design and power calculations.
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